1541 — ImmuneOnco Biopharmaceuticals Shanghai Income Statement
0.000.00%
Last trade - 00:00
- HK$4.86bn
- HK$4.94bn
- CNY0.39m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 5.07 | 0.538 | 0.386 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 737 | 403 | 378 |
Operating Profit | -732 | -402 | -378 |
Total Net Non Operating Interest Income / Expense | |||
Net Income Before Taxes | -733 | -403 | -379 |
Provision for Income Taxes | |||
Net Income After Taxes | -733 | -403 | -379 |
Net Income Before Extraordinary Items | |||
Net Income | -733 | -403 | -379 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -733 | -403 | -379 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -8.46 | -1.16 | -0.977 |